Fangsheng Pharma approves charter amendments, special dividend

Hunan Fangsheng Pharmaceutical (SSE:603998) announced the resolutions passed at its second extraordinary general meeting of shareholders held on February 14, 2025. Key approvals included the amendment of the company's articles of association, with 99.51% of votes in favor. Shareholders also approved a special dividend proposal for 2024, receiving 99.40% approval. The meeting was attended by shareholders representing 50.79% of the company's total voting shares. All seven company directors were present at the meeting, alongside three supervisors, with legal representation from Hunan Qiyuan Law Firm. The law firm confirmed the meeting's compliance with relevant laws, regulations, and the company's charter, ensuring the legitimacy of the procedures and resolutions. The board of directors has confirmed the resolution.